Peer-reviewed veterinary case report
Urine test for oxidative stress in dogs with bladder cancer
By Woolcock, Andrew D et al.·Published in Journal of veterinary internal medicine·2020·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Assessment of urinary 15-F-isoprostanes in dogs with urothelial carcinoma of the urinary bladder and other lower urinary tract diseases.
- Species:
- dog
Plain-English summary
A group of 117 dogs, including 46 with bladder cancer (urothelial carcinoma) and 30 with other urinary tract diseases, were tested for a substance in their urine called 15-F-isoprostanes, which might indicate urinary problems. The study found that dogs with urinary issues had higher levels of this substance compared to healthy dogs, but it wasn't effective for specifically detecting bladder cancer. Additionally, dogs with bladder cancer showed more signs of protein in their urine and blood in their urine than the other groups. Overall, urinary 15-F-isoprostanes didn't help in diagnosing bladder cancer, but further studies might explore its role in tracking inflammation and disease progression.
People also search for: dog bladder cancer symptoms · dog urinary tract disease treatment · elevated protein in dog urine
Abstract
BACKGROUND: The 15-F-isoprostanes are by-products of oxidative stress and are increased in the urine of people with lower urinary tract diseases (LUTD), especially urinary neoplasia. Urothelial carcinoma (UC) is the most common urinary neoplasm in dogs. Earlier detection of UC by noninvasive means could lead to improved outcomes. Urinary 15-F-isoprostanes potentially could provide this means, but have not been evaluated in dogs with UC. OBJECTIVE: The objective of this study was to measure urinary 15-F-isoprostanes in dogs with UC and dogs with other LUTD. ANIMALS: One hundred seventeen dogs: 46 dogs with UC, 30 dogs with LUTD, and 25 control dogs. METHODS: Any dog that was presented with dysuria was eligible for inclusion. Diagnosis of UC was confirmed histologically. Urinalysis was performed in each case, and 15-F-isoprostanes quantified by gas chromatography-negative ion chemical ionization-mass spectrometry (GC-NICI-MS) and normalized to urinary creatinine concentration. RESULTS: Dogs with urinary diseases (UC + LUTD) had higher median urinary 15-F-isoprostanes when compared to control dogs (5.92 ng/mg [range, 0.46-31.03] vs 3.73 [range, 1.8-7.98]; P = .02). Urinary 15-F-isoprostanes were similar in dogs with UC (5.33 ng/mg [range, 0.46-31.03]) compared to dogs with LUTD (6.29 ng/mg [range, 0.54-18.93]; P = .47) and control dogs (P = .06). Dogs with UC had higher qualitative measures of proteinuria (P = .004), hematuria (P = .01), and epithelial cells on urinalysis (P = .002) compared to the other groups. CONCLUSIONS AND CLINICAL IMPORTANCE: Urinary F-isoprostanes are not useful for the detection of UC in dogs. Future research could evaluate urinary 15-F-isoprostanes as a marker of inflammation in disease progression and prognosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32936493/